Latest Options News

Skylark Minerals has acquired a high-grade gold portfolio in Côte d'Ivoire, including a flagship project with a 364,600-ounce inferred resource, marking a significant step in its West African growth strategy. The company is fully funded to accelerate exploration in early 2026, targeting resource expansion and new discoveries.

Elementos Limited has announced a $2.9 million non-renounceable entitlement offer alongside a $6 million initial placement to fund key project developments, including the Oropesa Tin Project and Cleveland Tin and Tungsten Project.

Elementos Limited has secured a minimum $8.7 million capital raise led by Metals X, boosting its cash reserves to $12.5 million to advance key tin projects. The raise includes a $6 million unconditional placement and a pro-rata entitlement offer to shareholders.

Chariot Corporation and partners have formalized a phased small-scale mining initiative in Nigeria, aiming to unlock near-term lithium production while advancing larger exploration goals.

Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.

Noronex Limited has agreed to sell its Witvlei copper project in Namibia for A$4.5 million, enabling a sharper focus on its core Kalahari Copper Belt assets and uranium exploration. The staged payment deal includes options issuance and a royalty, signaling strategic portfolio refinement.

Power Minerals Limited has reported further high-grade niobium and rare earth element results from its Santa Anna project in Brazil, setting the stage for a significant 10,000m drilling campaign aimed at delivering a maiden resource estimate in early 2026.

AuKing Mining has completed a $400,000 share placement to fund its gold exploration efforts in Queensland’s Cloncurry region, with an extraordinary meeting set to approve new options.

DroneShield Limited reaffirms strong business fundamentals with record revenues in 2025, while addressing recent media reports and initiating an independent governance review.

Southern Palladium fast-tracks development at its Bengwenyama PGM Project, advancing drilling and infrastructure plans while securing key regulatory approvals.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for PYC-003, an RNA therapy targeting Polycystic Kidney Disease. This milestone moves the drug closer to pivotal Phase 2/3 trials.

Basin Energy has agreed to sell its Marshall Uranium Project to Green Canada Corporation, securing cash, shares, and a significant equity stake while retaining strategic rights and exposure to Canadian uranium assets.